LiveNova Logo

TandemLife is now a part of LivaNova, Learn More Here.

COVID-19 UPDATES:The U.S. Food and Drug Administration (FDA) issued guidance on April 6, 2020 to temporarily expand the availability of devices used in extracorporeal membrane oxygenation (ECMO) therapy to address the novel coronavirus (COVID-19) public health emergency. As a result of the guidance, cardiopulmonary devices, including select devices from TandemLife | LivaNova, are now temporarily indicated for ECMO therapy greater than 6 hours. To read the full announcement, click here.



855 336 3051 REIMBURSEMENT

800 373 1607 US

412 507 6182 INTERNATIONAL

News & Events



The United States Food and Drug Administration, on Monday, April 6, 2020, issued a guidance document to expand the availability of devices used for extracorporeal membrane oxygenation (ECMO) therapy to address the Coronavirus Disease 2019 (COVID-19) Pandemic. This policy is intended to remain in effect only for the duration of the public health emergency related

LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System

News & Press

LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System The versatile and compact system offers the power and simplicity to support more patients in more places.   LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new

2019 ACC Session & Expo


American College of Cardiology’s 68th Annual March 16-18, 2019 | Booth #653 Ernest N. Morial Convention Center | 900 Convention Center Blvd, New Orleans, LA 70130 TandemLife is the only MCS platform to offer a “Time to Decide™” Strategy, enabling simple, accessible, temporary ECLS support in minutes. Stop by Booth #653 to learn more about how

LivaNova Completes Acquisition of TandemLife

News & Press

London, April 4, 2018 – LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it closed its acquisition of TandemLife. Previously, on Feb. 14, LivaNova announced its intent to acquire TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions. “The acquisition of TandemLife allows us to complement

Priming with the TandemLife Sterile Basin

News & Press

The priming tray was designed to provide hospitals with a simple, repeatable priming process that can be implemented quickly wherever cardiopulmonary support is needed. Contact us here to learn more.

In his own words, Robert Barton describes his experience on TandemHeart support


Check out Robert Burton’s story of survival and journey to a kidney transplant.  Click HERE.

Dr. Christopher Overgaard (Peter Munk Cardiac Centre – UHN) discusses his recent use of the TandemHeart Device


In his own words – TandemHeart – Dr. Christoper Overgaard *Device duration varies by country. Indications for Use – USA TandemHeart Pump: The TandemHeart System is intended for extracorporeal circulatory support using an extracorporeal bypass circuit. Intended duration of use is for periods appropriate to cardiopulmonary bypass, up to six hours. It is also intended

First-in-Canada successful implant of cardiac-assist device in high-risk heart patient


-Courtesy of Peter Munk Cardiac Centre UHN- TandemHeart System offers new option to treat clinically-challenging cardiac condition A multi-disciplinary medical team of interventional and structural cardiologists at the Peter Munk Cardiac Centre, University Health Network, has successfully completed a Canadian first — the implant of a TandemHeart circulatory support device designed to take over the

The Next Era of CPR


Our company is working to simplify life support by focusing on ease of use for clinicians and accessibility for patients.  Our new TandemLife kit  will be packaged in a small, sterile basin so that emergent CBP can be initiated quickly in a variety of environments.  Click the link to learn how TandemLife is contributing to

ECLS Products among the Most Exciting Cardiac Care Developments


In a recent interview  Zain Khalpey, M.D (Director, Artificial Heart & ECMO Program, Banner University), describes the method of treating emergent cardiac failure situations with ECLS prior to full Left Ventricular unloading as the paradigm shift need to help improve results. Click the following link for the full interview:   _ _ _ _